,

PRIM concludes its succession plan with the announcement of Fernando Oliveros as the Group’s chief executive

Prim has approved the appointment of Fernando Oliveros as the company’s new Managing Director, who will join the company at the beginning of November. Fernando Oliveros, born in Mexico City in 1971, began his professional career with the…
,

The PRIM Group obtains its Family-Responsible Company certification

En 2020 el Grupo PRIM ha reforzado su compromiso con la conciliación y el desarrollo profesional, personal y social de sus colaboradores/as internos/as, con la obtención del sello efr, que le acredita como Empresa Familiarmente Responsable.
,

PRIM’s net profit reached €3.7 million in the first half of the year, following the impact of Covid-19

The Prim Group closed the first half of 2020 with a net profit of €3.7 million and an EBITDA of over €7.1 million, resulting in downturns of 31.7% and 30.1%, respectively. Every item on the income statement was affected by the pandemic…
,

PRIM improves its operating profit by 8.77% with an increase in sales of close to 10%

The Prim Group closed the first quarter of 2020 with a 9.46% increase in sales, bringing its net turnover to more than €38.3 million compared to €35 million during the same period in the previous year. This growth is the result of, among…
,

PRIM’s Board of Directors approves its succession plan at the top of the company

At its meeting today, the Board of Directors of Prim, S.A. approved a succession plan to renew the Company's leadership. This agreement is the culmination of the Action Plan approved by the Board in its meeting on 30 January 2019, which included…
,

PRIM reaches an agreement with Laboratorios Milo to purchase its Parapharmacy, Orthopaedic and Podiatry ranges.

This operation "strengthens" the Prim group’s presence in the Pharmaceutical sector and enables it to continue to enhance its growth strategy within the healthcare industry thanks to the complementary nature of both companies’ structures…